Clinical Trials | August 28, 2023
Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The company has new projects in development in Mumbai, Punjab, central and northern India, among others
Need to harmonize traditional and modern medicine to combat alarming health problems
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
Subscribe To Our Newsletter & Stay Updated
